# Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

> **NCT05204017** · — · RECRUITING · sponsor: **University of Alberta** · enrollment: 150 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Primary Lateral Sclerosis
- Progressive Muscular Atrophy
- Frontotemporal Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05204017
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-12
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204017, "Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05204017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*